Fewer Amputations as Diabetes Management Improves

Eileen Oldfield, Associate Editor
Published Online: Tuesday, July 17, 2012
Follow Pharmacy_Times:

Improvements in blood sugar control, foot care, and diabetes management contributed to a decline in leg and foot amputations in patients with diabetes, according to a study by the Centers for Disease Control and Prevention published in the January 2012 edition of Diabetes Care.

The rate of leg and foot amputations for adults 40 years and older declined by 65% between 1996 and 2008, from 11.2 per 1000 people in 1996 to 3.9 per 1000 people in 2008. The study results were adjusted for age, the CDC noted.

The study results also determined a higher rate of leg and foot amputations among men with diabetes than among women. In addition, it determined that blacks had higher rates of amputations than whites, with about 4.9 patients per 1000 requiring amputation compared with 2.9 patients per 1000.

Patients 75 years or older had the highest rate of amputation compared with other age groups, with 6.2 patients per 1000 requiring amputations.

Data from the National Hospital Discharge Survey on nontraumatic lower-limb amputations and from the National Health Interview Survey on the prevalence of diabetes were used in the report.

Pharmacists can help patients with diabetes manage their condition by stressing adherence to medication regimens, encouraging regular blood glucose monitoring, and providing education and support.

Pharmacists can stay current on the latest information in diabetes research and treatment with Diabetes Watch, which is available in Pharmacy Times and online at www.PharmacyTimes.com. For the top pharmacist-recommended products for patients with diabetes, including neuropathy products, foot care products, oral glucose products, and sugar-free sweeteners, visit the Diabetes Health Care section.

Related Articles
Sanofi has announced the FDA approval of its insulin glargine injection (Toujeo), a once-daily long-acting basal insulin, for the improvement of glycemic control in adults with type 1 and type 2 diabetes.
Novo Nordisk has positive results from a completed phase 2 trial on the oral formulation of its investigational, long-acting human glucagon-like peptide-1 analogue.
Many patients with non-alcoholic fatty liver disease also have low vitamin D levels.
Several studies have reported that controlling blood pressure with medication improves cardiovascular outcomes.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times